What is Tesamorelin?
Tesamorelin (brand name Egrifta) is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). It is the only FDA-approved GHRH peptide, originally indicated for reducing excess abdominal fat (visceral adiposity) in HIV-positive patients with lipodystrophy. It is one of the most potent GHRH analogs available.
Mechanism
Tesamorelin stimulates the pituitary gland to produce and release endogenous growth hormone. Unlike exogenous GH (which suppresses natural production), tesamorelin works with the body's feedback system, producing a more physiological GH pattern. Clinical trials showed significant reductions in visceral fat, improvements in lipid profiles, and increased IGF-1 levels.
Reconstitution
- 2 mg vial → 1 mL BAC water
- 5 mg vial → 2 mL BAC water
- 10 mg vial → 3 mL BAC water
Dosing
The FDA-approved dose is 2 mg injected subcutaneously once daily. Many research protocols use 1–1.28 mg daily, which may offer similar benefits with fewer side effects. Typically administered in the evening.
Contraindications
Tesamorelin is contraindicated in patients with active malignancy, pregnancy, or disruption of the hypothalamic-pituitary axis. Regular monitoring of IGF-1 levels is recommended.
Prescription medication. Educational purposes only. Consult a healthcare provider.